An Open Label, Single Arm, Multiple Dose Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of LNP023 When Administered in Addition to Standard of Care (SoC) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2018
At a glance
- Drugs LNP-023 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 21 Aug 2018 Planned primary completion date changed from 12 Dec 2019 to 15 Mar 2019.
- 31 Jul 2018 Planned End Date changed from 17 Dec 2018 to 12 Dec 2019.